Convatec Group Plc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BD3VFW73
GBP
2.32
0.02 (0.87%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

2.66 M

Shareholding (Jun 2025)

FII

0.26%

Held by 1 FIIs

DII

99.74%

Held by 1 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

High Debt Company with a Debt to Equity ratio (avg) at times

  • Poor long term growth as Operating profit has grown by an annual rate 8.16% of over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
  • The company has been able to generate a Return on Equity (avg) of 8.68% signifying low profitability per unit of shareholders funds
2

Poor long term growth as Operating profit has grown by an annual rate 8.16% of over the last 5 years

 
3

Positive results in Jun 25

4

With ROE of 13.52%, it has a expensive valuation with a 3.63 Price to Book Value

5

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 4,555 Million (Mid Cap)

stock-summary
P/E

27.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.65

stock-summary
Return on Equity

13.52%

stock-summary
Price to Book

3.45

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.37%
0%
-4.37%
6 Months
0.43%
0%
0.43%
1 Year
-6.98%
0%
-6.98%
2 Years
-4.05%
0%
-4.05%
3 Years
-0.77%
0%
-0.77%
4 Years
33.87%
0%
33.87%
5 Years
15.88%
0%
15.88%

Convatec Group Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
4.42%
EBIT Growth (5y)
8.16%
EBIT to Interest (avg)
4.08
Debt to EBITDA (avg)
2.16
Net Debt to Equity (avg)
0.63
Sales to Capital Employed (avg)
0.71
Tax Ratio
22.55%
Dividend Payout Ratio
69.52%
Pledged Shares
0
Institutional Holding
0.26%
ROCE (avg)
9.70%
ROE (avg)
8.68%

Valuation key factors

Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
3.63
EV to EBIT
19.82
EV to EBITDA
12.38
EV to Capital Employed
2.60
EV to Sales
3.11
PEG Ratio
1.65
Dividend Yield
NA
ROCE (Latest)
13.11%
ROE (Latest)
13.52%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.26%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Convatec Group Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 2.44% vs 13.52% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 105.09% vs -40.23% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,723.50",
          "val2": "1,682.50",
          "chgp": "2.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "402.80",
          "val2": "363.80",
          "chgp": "10.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "64.90",
          "val2": "45.60",
          "chgp": "42.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-39.60",
          "val2": "-62.80",
          "chgp": "36.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "104.80",
          "val2": "51.10",
          "chgp": "105.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "133.40%",
          "val2": "115.30%",
          "chgp": "1.81%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'23stock-summary

Dec'23
Dec'22
Change(%)
Net Sales
1,723.50
1,682.50
2.44%
Operating Profit (PBDIT) excl Other Income
402.80
363.80
10.72%
Interest
64.90
45.60
42.32%
Exceptional Items
-39.60
-62.80
36.94%
Consolidate Net Profit
104.80
51.10
105.09%
Operating Profit Margin (Excl OI)
133.40%
115.30%
1.81%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 2.44% vs 13.52% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 105.09% vs -40.23% in Dec 2022

stock-summaryCompany CV
About Convatec Group Plc stock-summary
stock-summary
Convatec Group Plc
Pharmaceuticals & Biotechnology
ConvaTec Group PLC is a United Kingdom-based medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions. It operates across market franchises, such as Advanced Wound Care, which provides advanced wound dressings and skin care products; Ostomy Care, which provides devices, accessories and services for people with a stoma, resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity and other causes; Continence and Critical Care, which provides products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida and other causes, and Infusion Devices, which provide disposable infusion sets.
Company Coordinates stock-summary
Company Details
Fl 7, 3 Forbury Place, 23 Forbury Road , READING None : RG1 3JH
Registrar Details